Migraine Therapeutics Research that Made News with Neurologists in 2024: Interview with Peter McAllister, MD
Significant strides were made in 2024 in evaluating a wide range of treatments for migraine, including phase 2 findings with PACAP inhibition, PI McAllister said.
Peter McAllister, MD, a neurologist and long-time principal investigator for landmark clinical trials of new migraine therapies, spoke with Patient Care© recently about the research he feels was headline news in the specialty in the last year and what those advances will mean for clinical care. In the short video above, McAllister points specifically to progress in the study of pituitary adenylate cyclase-activating polypeptide, or PACAP, inhibition and to the recent FDA approval of the neuromodulation device Nerivio for children as young as age 6 with migraine.
Peter McAllister, MD, is associate professor of neurology at the Yale University School of Medicine, in New Haven, CT and co-founder and medical director of the New England Institute for Neurology and Headache, chief medical officer of New England Institute for Clinical Research and Ki Clinical Research, president and chief executive officer of Ki Management Services, in Stamford CT.
